Indeed, in LT recipients, it is not only liver fibrosis stage that may cause graft damage, but also multiple liver pathologies that arise from the complex interaction between primary liver disease recurrence (hepatitis C, NAFLD), development of metabolic syndrome in the context of immunosuppression (calcineurin and mTOR inhibitors), and possible acute or chronic rejection. The gene discussed is MTOR; the disease is metabolic syndrome.